At Amarin, we are committed to improving the lives of high-risk cardiovascular patients across Europe by establishing innovative treatments for cardiovascular disease (CVD).
This advertorial is initiated, developed and funded by © Amarin Pharmaceutical Ireland Limited
Our vision at Amarin is to one day reach the moment when heart disease is no longer the leading cause of death in Europe. It is a bold vision, we know. But it is what drives us every single day. Knowing that because of what we do, someone, somewhere, is less likely to have a heart attack or stroke.
We have invested significant time and resources to realise this vision. We are building on our mission to deliver innovative therapies to help improve the lives of high-risk cardiovascular patients and, positively impact their families and society.
We are challenging the norms to introduce a new era of cardiovascular care. What’s more, our work is backed by ground-breaking clinical evidence that uses the latest scientific insights to reduce cardiovascular risk.
Cardiovascular Disease – Growing Health Burden
Amarin’s drive to establish a systematic change in CVD management is against the backdrop of a major challenge, as the problem of CVD grows ever more serious. The cost of CVD burden stands at €210 billion a year in Europe alone, with both the health and economic burden of CVD set to grow exponentially in Europe and across the globe in the coming years.1-3
CVD is responsible for 3.9 million deaths a year in Europe, with ischaemic heart disease, one of the main forms of CVD, being the single leading cause of death in both men and women.1
Although premature death from CVD (below 70 years) in high-income countries has fallen by 9% in women and 11% in men since 2010, it is a different story in middle-income countries, where rates have declined by only 8% in women and 2% in men.2 The prevalence of type 2 diabetes, a major risk factor for CVD, has also increased rapidly over the last ten years and now affects an estimated 60 million people in Europe.1,2
Current Treatments and Limitations
For the past 30 years, therapies to treat CVD have been focused on lowering LDL cholesterol (LDL-C), and with success.4 Yet LDL-C is not the full story; despite achieving target LDL-C levels (often defined as <70mg/dl), some patients are still at significant residual cardiovascular risk that exists beyond traditional therapies to treat CVD.4
At Amarin, we passionately believe the need to address the residual risk of CVD in Europe is monumental. To do this, we need to look beyond LDL-C targeted therapies, as many people are still dying of heart attacks and strokes.
The Need to Rethink Residual Cardiovascular Risk Prevention
The role of elevated triglycerides – another type of lipid found in the blood – is being increasingly recognised as a risk factor for CVD.5 Epidemiological studies have shown that elevated fasting triglyceride levels are associated with incident cardiovascular events.6 Data from the Copenhagen General Population studies showed that a single elevated non-fasting triglyceride measurement was associated with increased risk for myocardial infarction, ischaemic heart disease and death.7
Epidemiological and Mendelian randomisation studies (which use genetic alterations to differentiate correlation from causation in observational data) have pointed towards a role for elevated triglycerides in atherosclerosis, resulting from remnant cholesterol (the cholesterol contained in triglyceride-rich lipoproteins) particles.8
What is Amarin Doing to Reduce Residual CVD Risk Burden?
Founded in the UK in 1989 and with offices in Ireland (global headquarters are in Dublin), Switzerland (Zug) and the United States (New Jersey), Amarin has over 1,000 employees, commercial partners, and suppliers across the world. Having achieved a strong presence in the United States, we are now embarking on creating a new company infrastructure in Europe, building a local company presence in all major European markets.
For patients, each day brings new worries about the effects of CVD, not only on their own lives but also on those of their families and loved ones. Therefore, we have made it our mission to develop innovative treatments for those at risk of suffering a heart attack, stroke or similar serious cardiovascular events. In Europe, the time has come for a systematic change in how this disease is treated, and at Amarin, we have an opportunity to do things differently and be part of the solution.
Through our dedicated research into these areas, we are striving to offer alternative therapies that can improve the quality of life for patients. At Amarin, we are part of the wider treatment landscape and management, shaping the future of CVD treatments along with other players in the field.
In today’s life science industry, changing the CVD treatment paradigm is not an easy task. However, we are passionate about improving the lives of patients across Europe. There are thousands of people – now and in the future – relying on us to get this right, and we have a once-in-a-lifetime chance to do just that.
- European Heart Network. European Cardiovascular Disease Statistics 2017. https://ehnheart.org/cvd-statistics/cvd-statistics-2017.html Accessed March 2022.
- ESC Cardiovascular Realities 2020. https://www.flipsnack.com/Escardio/esc-cardiovascular-realities-2020/full-view.html Accessed March 2022
- Roth GA, Mensah GA, Johnson CO et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021.
- Ganda OP, Bhatt DL, Mason, RP, et al. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. J Am Coll Cardiol. 2018;72(3):330-343.
- Aberra T, Peterson ED, Pagidipati NJ et al. The Association Between Triglycerides and Incident Cardiovascular Disease: What Is “optimal”? J Clin Lipidol. 2020;14(4):438-447.e3.
- Mason RP, Libby P, Bhatt DL. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. Arterioscler Thromb Vasc Biol. 2020; 40(5):1135-1147.
- Nordestgaard BG, Benn M, Schnohr P et al. Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women. JAMA. 2007;298(3):299-308.
- Virani S, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 78(9):960-993.